244 related articles for article (PubMed ID: 30538293)
1. ALK positively regulates MYCN activity through repression of HBP1 expression.
Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
[TBL] [Abstract][Full Text] [Related]
2. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
3. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
5. The expression of the tumour suppressor HBP1 is down-regulated by growth factors via the PI3K/PKB/FOXO pathway.
Coomans de Brachène A; Bollaert E; Eijkelenboom A; de Rocca Serra A; van der Vos KE; Burgering BM; Coffer PJ; Essaghir A; Demoulin JB
Biochem J; 2014 May; 460(1):25-34. PubMed ID: 24762137
[TBL] [Abstract][Full Text] [Related]
6. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
7. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
[No Abstract] [Full Text] [Related]
8. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
9. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
10. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
[TBL] [Abstract][Full Text] [Related]
12. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
13. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
14. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
[TBL] [Abstract][Full Text] [Related]
15. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
[No Abstract] [Full Text] [Related]
16. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
17. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
18. ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Huang M; Fang W; Farrel A; Li L; Chronopoulos A; Nasholm N; Cheng B; Zheng T; Yoda H; Barata MJ; Porras T; Miller ML; Zhen Q; Ghiglieri L; McHenry L; Wang L; Asgharzadeh S; Park J; Gustafson WC; Matthay KK; Maris JM; Weiss WA
Cell Rep; 2024 Mar; 43(3):113927. PubMed ID: 38451815
[TBL] [Abstract][Full Text] [Related]
19. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
20. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
